SCHEMBL2021806

SCHEMBL2021806

c1ccc2cc(-c3nnc(-c4cn5c6c(cccc46)CCC5)o3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.44
HPGD P15428 5/20 0.44
HSD17B10 Q99714 4/20 0.44
CYP1A2 P05177 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TSHR P16473 3/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 1/20 0.44
KDM4E B2RXH2 6/20 0.42
RAB9A P51151 3/20 0.42
CYP2C19 P33261 1/20 0.42
ATM Q13315 1/20 0.42
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
OPA1 O60313 1/20 0.37
EIF5B O60841 1/20 0.37
MET P08581 1/20 0.37
HMOX2 P30519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021453 0.86 RAB9A (0.49) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2016789 0.85 HTR2A (0.44) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2015078 0.85 HTR2A (0.43) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2020106 0.83 RAB9A (0.48) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2015370 0.83 NPC1 (0.48) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2019352 0.83 NPC1 (0.46) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2020602 0.83 NPC1 (0.44) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2020405 0.83 NPC1 (0.43) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2015858 0.83 RAB9A (0.48) ALDH1A1HPGDHSD17B10CYP1A2SMN1; SMN2
SCHEMBL2023138 0.83 KDM4E (0.48) ALDH1A1HPGDHSD17B10SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-8563567-B2 Substituted heterocyclic compounds ARQULE, INC. (US) 2013-10-22 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160237-A1 Substituted Heterocyclic Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160237-A1 Substituted Heterocyclic Compounds MKI67, CCNC, NQO1 ALDH1A1 178/4885HPGD 39/4885HSD17B10 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.